A federal judge in Delaware on Friday ruled in favor of the Biden administration in AstraZeneca's attempt to overturn Medicare drug price negotiations under the Inflation Reduction Act. This was the second failed challenge to the law in the past month.

U.S. District Judge Colm Connolly's decision came the day before the drugmaker was due to respond to the U.S. government's initial bid for the price of its diabetes drug Farxiga. The opinion made clear that AstraZeneca's constitutional challenge should not move forward because the company "has no legitimate claim of entitlement to sell its drugs to the government at any price other than what the government is willing to pay," meaning "its due process claim fails as a matter of law."

AstraZeneca's "desire" or even "expectation" to sell its drugs to the government "at the higher prices it once enjoyed does not create a protected property interest," according to the ruling.